Company / SG&A Expense
CG Oncology, Inc. SG&A Expense History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$73.5M
FY2025
5-year range
$9.9M / $73.5M
FY2023-FY2025
Trend
+118.2%
vs FY2024
Sector context
#131 of 213
Health Care
What the data says
At $74M, CG Oncology, Inc.'s sg&a expense ranks #83 of 213 in the Health Care sector. Increased from $10M to $74M over the past 2 years.
Based on SEC 10-K filings.
$74M in FY2025.
Increased from $10M to $74M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#83 of 213 in Health CareTop 38% of 213This company $73.5M Sector average $722.3M
▼
-89.8% below sector average
Key checks
Key Insights
- In FY2025, sg&a expense increased 118.2% year-over-year.
- Ranks #131 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 8.02 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $73.5M | +118.2% |
| FY2024 | $33.7M | +240.4% |
| FY2023 | $9.9M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026